CAH: Guidance Lift and Pharma Momentum

Executive Summary

Company Overview

Cardinal Health Inc ($CAH) is a leading medical products and pharmaceutical distributor serving hospitals, pharmacies, ambulatory surgery centers and physician offices. The company operates an extensive logistics and distribution network that supplies pharmaceuticals, medical and surgical products, and data-driven supply chain services.

Key Products & Competitive Position

• Core Business: Large-scale pharmaceutical distribution and medical-surgical products distribution across the U.S. and international markets.
• Key Products: Generic and branded drug distribution, specialty pharma logistics, branded and private-label medical-surgical supplies, and supply-chain services and solutions.
• Competitive Moat: Deep national distribution network, long-term contracts with health systems and pharmacies, large-scale purchasing power, and data-enabled inventory management capabilities.

Recent Developments

In March 2026 $CAH raised fiscal 2026 adjusted EPS guidance to $10.15-$10.35, citing strong pharmaceutical segment growth and margin expansion. The company also announced the planned retirement of Chief Accounting Officer Mary Scherer in February 2027, and will identify a successor to ensure a smooth transition. Market commentary highlighted $CAH as IBD's Stock of the Day and analysts including Barclays have nudged price targets higher in recent weeks.

Financial Snapshot

Revenue & Earnings Trends

Company commentary and third-party reports point to year-over-year revenue growth of roughly 19% and an adjusted EPS acceleration of about 36% in the most recent reporting window. Management's raised FY26 guidance to $10.15-$10.35 on the back of pharmaceutical segment strength implies continued top-line momentum and margin recovery. Trailing EPS is $6.95, while forward consensus and the guidance range imply materially higher earnings power in FY26.

Balance Sheet Highlights

$CAH has a market cap of $51.08B and an enterprise value near $57.33B. The company's current ratio stands at 0.91, indicating current liabilities exceed current assets by a small margin and suggesting working capital is an area to watch. Return on equity is high at 37.17 percent, reflecting strong profitability and capital efficiency. Net leverage and free cash flow generation support capital deployment, but liquidity timing and receivables/inventory management remain important.

Valuation Analysis

Historical Comparison

Trailing P/E near 30.7 is above the company's 5-year average multiple, reflecting a rerating driven by stronger growth and margin improvement. Forward multiples are friendlier at about 19, which lines up with mid-teens to low-20s multiples for large medical distributors as earnings normalize after recent gains. The market has increasingly priced in improved operational execution and a brighter pharma backdrop.

Fair Value Estimate

Using the midpoint of FY26 guidance, adjusted EPS around $10.25 and applying a conservative forward multiple of 19 yields an indicative fair value near $195. That provides a conservative base case. A consensus-driven multiple closer to 24 to 25, which reflects analyst enthusiasm and durable margin expansion, implies a valuation closer to $245-$256. Analysts' mean target near $249 implies the market is pricing a more optimistic scenario than the conservative DCF-style multiple.

Competitive Landscape

Key Competitors

Competitive Advantages

• Moat 1: Scale and national fulfillment network, which lowers per-unit distribution costs and shortens delivery times.
• Moat 2: Long-term partnerships with health systems and retail pharmacies, which create revenue stickiness and contracting leverage.
• Moat 3: Data-driven inventory and supply-chain tools that reduce stock-outs and optimize working capital.

Earnings Track Record

Recent Earnings History

Guidance Trend

Management raised fiscal 2026 guidance to $10.15-$10.35 adjusted EPS, reflecting upward revisions to revenue and margin assumptions driven by the pharmaceutical segment. The guidance raise is an important signal that the company sees sustained demand and improved mix. You'll want to track whether management narrows the range or provides more granularity on specialty distribution and margin drivers ahead of Q3 2026 results on April 29.

Analyst Sentiment

Price Targets

• Low: $200.00
• Mean: $249.27 (+14.8% upside)
• High: $275.00

Recent Analyst Actions

Barclays maintained an Overweight rating and raised its price target from $243 to $258 on 2/24/2026. Multiple firms have adjusted targets upward after Cardinal's guidance raise and the stronger-than-expected earnings cadence. The analyst community is broadly constructive, which explains the Strong Buy consensus and positive target dispersion.

Recent News & Catalysts

Key Developments

• Guidance Raise (3/2026): Fiscal 2026 adjusted EPS guidance increased to $10.15-$10.35 following stronger pharmaceutical segment performance.
• CAO Retirement: Chief Accounting Officer Mary Scherer plans to retire in Feb 2027, with management planning a controlled succession process to limit disruption.
• Market Recognition: Named IBD Stock of the Day and flagged in multiple market write-ups as a resilient medical distributor amid macro uncertainty.

Upcoming Catalysts

Technical Outlook

Trend Analysis

Shares have moved sharply higher over the last 12 months, reflecting improving fundamentals and multiple expansion. Momentum remains positive, though the stock is trading below its recent peak from early March. Volatility has eased relative to the broader market, consistent with a beta of 0.67, which suggests $CAH may behave as a defensive growth-like holding in healthcare exposure.

Key Levels

• Resistance: $233.60, $258
• Support: $200, $180

Bull vs Bear Case

Risks to Consider

Bottom Line

Action Items for Investors

• Long-term investors: Monitor FY26 guidance execution, free cash flow consistency, and CAO succession updates before materially changing exposure. Track whether margins narrow or expand against the raised guidance.
• Short-term traders: Watch price reaction to the April 29 earnings release, compare results to the raised guidance, and use resistance at $233.60 and $258 as trade references.
• Risk management: Keep an eye on working capital metrics, current ratio trends, and any accounting or governance developments that could increase volatility or disclosure risk.

What to Watch This Week

• Analyst notes and revisions following the guidance raise and CAO succession plan updates.
• Market commentary and technical momentum around the $233.60 52-week high.
• Macro headlines that could affect healthcare volumes and distributor demand, such as policy news or payer developments.